Glypican-1 Overexpression in Different Types of Breast Cancers
Fatemah O F O Alshammari,Yousef M Al-Saraireh,Ahmed M M Youssef,Yahya M AL-sarayra,Hamzeh Mohammad Alrawashdeh,Fatemah OFO Alshammari,Ahmed MM Youssef
DOI: https://doi.org/10.2147/OTT.S315200
IF: 4
2021-07-31
OncoTargets and Therapy
Abstract:Fatemah OFO Alshammari, 1 Yousef M Al-Saraireh, 2 Ahmed MM Youssef, 3 Yahya M AL-sarayra, 4 Hamzeh Mohammad Alrawashdeh 5 1 Department of Medical Lab technology, Faculty of health sciences, The Public Authority for Applied Education and Training, Kuwait, Kuwait; 2 Department of Pharmacology, Faculty of Medicine, Mutah University, Al-karak, Jordan; 3 Department of Pharmacology, Faculty of Pharmacy, Mutah University, Al-karak, Jordan; 4 Al-karak Governmental hospital, Al-Karak, Jordan; 5 Department of Ophthalmology, Sharif Eye Centers, Irbid, Jordan Correspondence: Yousef M Al-Saraireh Department of Pharmacology, Faculty of Medicine, Mutah University, PO. Box: 7, Al-karak, 61710, Jordan Tel +962 799172658 Email Purpose: Treatment of metastatic breast cancer patients is challenging and remains a major underlying cause of female mortality. Understanding molecular alterations in tumor development is critical to identify novel biomarkers and targets for cancer diagnosis and therapy. One of the aberrant cancer expressions gaining recent research interest is glypican-1. Several studies reported strong glypican-1 expression in various types of human cancers. However, none of these investigated glypican-1 expression in a large cohort of breast cancer histopathological subtypes. Patients and Methods: Immunohistochemistry was used to assess glypican-1 expression in 220 breast cancer patients and its relation to demographic and clinical features, as well as important prognostic immunohistochemical markers for breast cancer. Results: Intense glypican-1 expression was recognized in all breast cancer histopathological subtypes. Normal, healthy breast tissue displayed a heterogeneous low expression (20%). Importantly, a strong differential in glypican-1 expression was determined between normal and malignant breast tissues. Moreover, there was a significantly high rate of glypican-1 expression in advanced grades of breast cancer patients and larger tumor sizes. Unfortunately, the glypican-1 expression demonstrated no obvious relationship with the expression of various biomarkers in breast cancer. Conclusion: This study may establish glypican-1 as a promising new therapeutic target for the development of therapy in breast cancer. Keywords: cancer, glypicans, immunohistochemistry, protoglycans, heparan sulfate proteoglycans Breast cancer is the most prevalent type of cancer among women, making up 11.6% of the cancer morbidity burden and 6.6% of the cancer mortality rate worldwide. In 2018, 2 million women (24.2%) were newly diagnosed with breast cancer and more than 0.6 million (15.0%) women died from this cancer worldwide. 1 Despite the substantial improvement in prognosis of breast cancer patients, approximately one-third of the patients die from metastatic disease, especially in the brain. Even with the recent advances in the treatment of breast cancer, concerns about diagnostic methods and effective treatment options remain unresolved. 2 , 3 Therefore, new biomarkers for the detection of early-stage breast cancer and new therapies for better management of metastatic disease are urgently needed. Glypicans are a family of proteins belonging to heparan sulfate proteoglycans (HSPGs). They are attached to extracellular surfaces via a glycosyl-phosphatidylinositol anchor. 4 To date, there are six types comprising this family in mammals, recognized as Glypican-1 to Glypican-6. These are predominantly expressed during organ development, particularly in morphogenesis, and their levels change in a stage and tissue-specific manner. 5 , 6 Their main function is believed to control cell signalling through cell interactions, Wnt and Sonic hedgehog (Shh) activation, and growth factor binding, such as fibroblast growth factor (FGF), insulin-like growth factor (IGF), and vascular endothelial growth factor (VEGF). These signalling pathways participate in the regulation of cell proliferation, motility, differentiation, organ development and metabolism. 7 Several studies demonstrated the role of glypicans in regulating the cell growth and tumorigenesis in many cancers. 8 Of recent importance is the aberrant expression of glypican-1 in several types of cancers and its association with cancer development. Glypican-1 expression was found to be higher in patients with pancreatic cancer than in chronic pancreatitis patients and healthy controls. 9 This expression was significantly as -Abstract Truncated-
oncology,biotechnology & applied microbiology